Arrowhead Pharmaceuticals reported significant revenue from collaborations with Novartis ($89.0 million) and Madrigal ($25.0 million) in fiscal 2026, while total R&D expenses rose 22% to $739.1 million due to pipeline progression. A major one-time operating expense of $215.0 million was recorded for the acquisition of a Priority Review Voucher to accelerate the plozasiran sNDA.
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2026, highlighting the commercial launch of REDEMPLO for familial chylomicronemia syndrome (FCS). The company reported 950 cumulative prescriptions since launch and announced that the FDA granted plozasiran entry into the STAR pilot program for severe hypertriglyceridemia, qualifying it for a 6-month priority review.
Term
FY2026
“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth.”
Christopher Anzalone, Ph.D., President and CEO
“I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”
Arrowhead Pharmaceuticals $400M Debt Financing with Sixth Street Lending Partners
Arrowhead Pharmaceuticals refinanced its existing senior secured term loans by entering into a new $400 million Amended and Restated Financing Agreement with Sixth Street. The new facility significantly lowers borrowing costs from a 15% fixed rate to SOFR plus 5.50%, extends the maturity to November 2031, and eliminates previous requirements to sweep commercial revenue or milestone payments for debt repayment.